Halozyme (HALO) CEO logs RSU vesting and tax-withholding share dispositions

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley reported equity compensation activity involving restricted stock units and related common stock. On February 20 and 23, 2026, restricted stock units vested and were settled into a total of 22436 and 16757 shares of common stock through derivative exercises.

On both dates, a portion of the newly delivered common shares, 9040 and 12104 shares respectively, was automatically withheld by the issuer to cover tax withholding obligations at prices of $70.98 and $70.64 per share, rather than sold in open‑market transactions. After these transactions, Torley directly owned 767780 shares of common stock and 44872 restricted stock units.

Insider Trade Summary

39,193 shares exercised/converted

Mixed 6 txns

Insider Torley Helen

Role PRESIDENT AND CEO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	22,436	$0.00	--
Exercise	Common Stock	22,436	$0.00	--
Tax Withholding	Common Stock	12,104	$70.64	$855K
Exercise	Restricted Stock Units	16,757	$0.00	--
Exercise	Common Stock	16,757	$0.00	--
Tax Withholding	Common Stock	9,040	$70.98	$642K

Holdings After Transaction: Restricted Stock Units — 44,872 shares (Direct); Common Stock — 779,884 shares (Direct)

Footnotes (1)

1. The reported disposition of 9,040 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. The reported disposition of 12,104 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Torley Helen

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		M		16,757	A	$0	766,488	D
Common Stock	02/20/2026		F		9,040(1)	D	$70.98	757,448	D
Common Stock	02/23/2026		M		22,436	A	$0	779,884	D
Common Stock	02/23/2026		F		12,104(2)	D	$70.64	767,780	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	02/20/2026		M			16,757	(3)	(3)	Common Stock	16,757	$0	50,270	D
Restricted Stock Units	$0	02/23/2026		M			22,436	(3)	(3)	Common Stock	22,436	$0	44,872	D

Explanation of Responses:

1. The reported disposition of 9,040 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

2. The reported disposition of 12,104 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

3. This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did HALO (Halozyme Therapeutics) CEO Helen Torley report on this Form 4?

Helen Torley reported vesting and settlement of restricted stock units into Halozyme common stock, along with share dispositions used solely to satisfy tax withholding obligations. These transactions reflect routine equity compensation activity rather than open‑market purchases or sales of HALO shares.

How many Halozyme (HALO) shares did Helen Torley acquire through RSU vesting?

Helen Torley acquired 22436 Halozyme common shares on February 23, 2026, and 16757 shares on February 20, 2026, through the vesting and settlement of restricted stock units. These derivative exercises converted RSUs into directly held common stock at no cash exercise price.

Were any of Helen Torley’s Halozyme (HALO) shares sold on the open market?

The filing shows no open‑market sales. Instead, 9040 shares and 12104 shares of common stock were withheld by the issuer to pay tax withholding obligations. Footnotes clarify these dispositions were tax payments, not discretionary sales into the public market.

What is Helen Torley’s Halozyme (HALO) ownership after these Form 4 transactions?

After the reported transactions, Helen Torley directly owned 767780 shares of Halozyme common stock and 44872 restricted stock units. These figures reflect her updated direct holdings following RSU vesting, share delivery, and shares withheld for tax obligations on February 20 and 23, 2026.

What do the tax-withholding dispositions mean in the Halozyme (HALO) Form 4?

The dispositions coded “F” represent shares withheld by Halozyme to cover tax obligations triggered by RSU vesting. Footnotes state 9040 and 12104 shares were retained by the issuer for tax withholding, indicating an automatic payroll-like process rather than voluntary stock sales.